{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-038528","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.329668+00:00","generated_at":"2026-06-15T05:19:18.659580+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ImmuCell Q1 product sales down 43% to $3.4M; net loss $2.3M due to contamination","bullets":["Product sales fell 43% YoY to $3.4M; net loss of $2.3M ($0.30/basic share) vs net income of $513K ($0.07 diluted) in Q1 2022.","Gross margin collapsed to 9% from 52% on write-off of contaminated inventory and production slowdown.","Order backlog surged to ~$8M as of May 3, 2023, from $2.5M at Dec 31, 2022, due to reduced output.","Cash dropped to $3.1M from $5.8M; EBITDA turned negative to ($1.6M) from $1.2M a year ago.","Remediation efforts underway; management targets $6M quarterly production run-rate (80% of $30M capacity)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-038528","json":"https://secwatch.observer/filing/0001213900-23-038528.json","markdown":"https://secwatch.observer/filing/0001213900-23-038528.md","text":"https://secwatch.observer/filing/0001213900-23-038528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390023038528/0001213900-23-038528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390023038528/ea178219-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:19:18.659580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa1ee8f0f3a2191624d7eeda5bc258939dca612a","claim":"IMMUCELL CORP /DE/ reported the quarter ended March 31, 2023 results: revenue $3.4 million, net income ($2.3) million, EPS ($0.30) per basic share.","evidence_excerpt":"Product sales decreased by 43%, or $2.6 million, to $3.4 million during the three-month period ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390023038528/0001213900-23-038528-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$3.4 million"},{"label":"Net income","value":"($2.3) million"},{"label":"EPS","value":"($0.30) per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}